×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VTVT – vtv therapeutics inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VTVT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
07:04 pm
vtvt
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
Neutral
Report
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
12/19
09:09 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/18
04:36 pm
vtvt
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
Low
Report
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
12/18
04:05 pm
vtvt
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Medium
Report
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
12/16
04:42 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/10
04:12 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/2
03:47 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/25
01:59 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
5/15/2025
04:01 pm
vtvt
vtv therapeutics inc. - class a
MISS
Report
-6.2%
vtv therapeutics inc. - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
05:11 pm
vtvt
Form 8-K vTv Therapeutics Inc. For: Dec 19
Neutral
Report
Form 8-K vTv Therapeutics Inc. For: Dec 19
12/9
04:18 pm
vtvt
Form SCHEDULE 13D/A vTv Therapeutics Inc. Filed by: Samsara BioCapital, L.P.
Medium
Report
Form SCHEDULE 13D/A vTv Therapeutics Inc. Filed by: Samsara BioCapital, L.P.
11/25
06:04 am
vtvt
Form EFFECT vTv Therapeutics Inc.
Medium
Report
Form EFFECT vTv Therapeutics Inc.
11/12
10:30 am
vtvt
Form SCHEDULE 13G/A vTv Therapeutics Inc. Filed by: Invus Global Management, LLC
Medium
Report
Form SCHEDULE 13G/A vTv Therapeutics Inc. Filed by: Invus Global Management, LLC
11/6
04:32 pm
vtvt
Form 10-Q vTv Therapeutics Inc. For: Sep 30
Medium
Report
Form 10-Q vTv Therapeutics Inc. For: Sep 30
11/6
04:28 pm
vtvt
Form 8-K vTv Therapeutics Inc. For: Nov 06
Low
Report
Form 8-K vTv Therapeutics Inc. For: Nov 06
10/3
04:39 pm
vtvt
Form S-3 vTv Therapeutics Inc.
Medium
Report
Form S-3 vTv Therapeutics Inc.
9/25
05:07 pm
vtvt
Form SCHEDULE 13D/A vTv Therapeutics Inc. Filed by: Samsara BioCapital, L.P.
Low
Report
Form SCHEDULE 13D/A vTv Therapeutics Inc. Filed by: Samsara BioCapital, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/7
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
52.4%
2/20 Q4/2019 12/31/2019 EPS -0.110 ZacksConsensus N/A ActVsEst N/A - N/A 15.5%
1/7 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 15.3%
12/23 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 13.4%
5/16 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 13.0%
7/15 vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference 12.3%
9/11 Form 8-K vTv Therapeutics Inc. For: Sep 11 8.8%
1/28 Form 8-K vTv Therapeutics Inc. For: Jan 28 7.8%
8/16 vTv Therapeutics Inc (NASDAQ: VTVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. 7.3%
9/4 Form 4 vTv Therapeutics Inc. For: Sep 04 Filed by: PERELMAN RONALD O 6.9%
2/20 Q4/2019 12/31/2019 EPS -0.110 ZacksConsensus N/A ActVsEst N/A - N/A 15.5%
1/7 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 15.3%
12/23 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 13.4%
5/16 Form SC 13D/A vTv Therapeutics Inc. Filed by: MacAndrews & Forbes Inc. 13.0%
7/15 vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference 12.3%
9/11 Form 8-K vTv Therapeutics Inc. For: Sep 11 8.8%
1/28 Form 8-K vTv Therapeutics Inc. For: Jan 28 7.8%
8/16 vTv Therapeutics Inc (NASDAQ: VTVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. 7.3%
9/4 Form 4 vTv Therapeutics Inc. For: Sep 04 Filed by: PERELMAN RONALD O 6.9%
TOP News Decliners
3/11
Form 4 vTv Therapeutics Inc. For: Mar 10 Filed by: KINDLER JEFFREY B
-21.6%
6/6 vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes -18.9%
2/10 Vtv Therapeutics up 67% premarket on positive TTP399 data [Seeking Alpha] -16.7%
2/28 vTv Therapeutics Inc (NASDAQ: VTVT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -9.0%
9/18 Form 4 vTv Therapeutics Inc. For: Sep 18 Filed by: PERELMAN RONALD O -8.1%
7/31 vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update -7.7%
3/18 vTv Therapeutics Inc (NASDAQ: VTVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.9%
5/6 vTv Therapeutics Inc (NASDAQ: VTVT) was upgraded by analysts at Northland Securities from a "market perform" rating to an "outperform" rating. -6.8%
9/18 vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes -6.5%
5/30 vTv Therapeutics Inc (NASDAQ: VTVT) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -6.2%
6/6 vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes -18.9%
2/10 Vtv Therapeutics up 67% premarket on positive TTP399 data [Seeking Alpha] -16.7%
2/28 vTv Therapeutics Inc (NASDAQ: VTVT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -9.0%
9/18 Form 4 vTv Therapeutics Inc. For: Sep 18 Filed by: PERELMAN RONALD O -8.1%
7/31 vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update -7.7%
3/18 vTv Therapeutics Inc (NASDAQ: VTVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. -6.9%
5/6 vTv Therapeutics Inc (NASDAQ: VTVT) was upgraded by analysts at Northland Securities from a "market perform" rating to an "outperform" rating. -6.8%
9/18 vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes -6.5%
5/30 vTv Therapeutics Inc (NASDAQ: VTVT) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: